News | December 22, 2024
Shilpa Medicare’s Unit VII, Nacharam, Hyderabad receives GMP certificate from EMA, Austria
The company has received the GMP Certification after successful closure of the inspection
The company has received the GMP Certification after successful closure of the inspection
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
